kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
Company profile
Ticker
KALV
Exchange
Website
CEO
Thomas Crockett
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Carbylan Biosurgery Inc, Carbylan Biosurgery, Inc, Carbylan Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
KalVista Pharmaceuticals Limited • KalVista Securities Holding Corporation • KalVista Pharmaceuticals (Ireland) Limited ...
KALV stock data
Latest filings (excl ownership)
8-K
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
22 Apr 24
8-K
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
11 Mar 24
10-Q
2024 Q3
Quarterly report
11 Mar 24
8-K
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
7 Mar 24
8-K
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
16 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
8-K
Termination of a Material Definitive Agreement
14 Feb 24
8-K
Regulation FD Disclosure
13 Feb 24
S-8
Registration of securities for employees
9 Jan 24
Latest ownership filings
4
William Fairey
22 Apr 24
3
William Fairey
22 Apr 24
SC 13D/A
TCG Crossover GP I, LLC
1 Apr 24
4
Benjamin L Palleiko
8 Mar 24
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
26 Feb 24
4
Bong Y Koh
22 Feb 24
SC 13D/A
Frazier Life Sciences Public Fund, L.P.
22 Feb 24
4
Edward P. Feener
21 Feb 24
4
Christopher Yea
21 Feb 24
4
Benjamin L Palleiko
21 Feb 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.67 mm | 57.67 mm | 57.67 mm | 57.67 mm | 57.67 mm | 57.67 mm |
Cash burn (monthly) | (no burn) | (no burn) | 9.92 mm | 9.79 mm | 6.61 mm | 6.54 mm |
Cash used (since last report) | n/a | n/a | 57.30 mm | 56.59 mm | 38.19 mm | 37.80 mm |
Cash remaining | n/a | n/a | 363.18 k | 1.07 mm | 19.48 mm | 19.87 mm |
Runway (months of cash) | n/a | n/a | 0.0 | 0.1 | 2.9 | 3.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 109 |
Opened positions | 18 |
Closed positions | 10 |
Increased positions | 34 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 346.79 bn |
Total shares | 52.42 mm |
Total puts | 417.70 k |
Total calls | 1.10 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Management | 3.44 mm | $33.13 bn |
TCG Crossover GP I | 3.41 mm | $21.20 mm |
TCG Crossover Management | 3.40 mm | $32.70 bn |
Frazier Life Sciences Management | 3.24 mm | $31.19 bn |
Tang Capital Partners | 3.20 mm | $0.00 |
VR Adviser | 2.92 mm | $28.09 bn |
Venrock Healthcare Capital Partners III | 2.92 mm | $18.14 mm |
Suvretta Capital Management | 2.42 mm | $23.31 bn |
Venrock Healthcare Capital Partners II | 2.04 mm | $34.59 mm |
Saturn V Capital Management | 1.81 mm | $17.43 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | William Fairey | Stock Option Common Stock | Grant | Acquire A | No | No | 11.5 | 17,000 | 195.50 k | 17,000 |
6 Mar 24 | Benjamin L Palleiko | RSU Common Stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 250,000 |
20 Feb 24 | Venrock Healthcare Capital Partners III | Pre-Funded Warrants Common Stock | Buy | Acquire P | Yes | No | 15.249 | 655,738 | 10.00 mm | 655,738 |
20 Feb 24 | Paul K. Audhya | Common Stock | Sell | Dispose S | No | No | 14.115 | 14,295 | 201.77 k | 52,886 |
17 Feb 24 | Paul K. Audhya | Common Stock | Option exercise | Acquire M | No | No | 0 | 30,613 | 0.00 | 67,181 |
17 Feb 24 | Paul K. Audhya | Performance Stock Units Common Stock | Option exercise | Dispose M | No | No | 0 | 12,083 | 0.00 | 36,250 |
17 Feb 24 | Paul K. Audhya | Performance Stock Units Common Stock | Option exercise | Dispose M | No | No | 0 | 12,083 | 0.00 | 12,084 |
17 Feb 24 | Paul K. Audhya | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,028 | 0.00 | 28,195 |
17 Feb 24 | Paul K. Audhya | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,419 | 0.00 | 21,769 |
News
Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
11 Apr 24
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $24 Price Target
12 Mar 24
Needham Maintains Buy on KalVista Pharma, Maintains $35 Price Target
11 Mar 24
Recap: KalVista Pharma Q3 Earnings
11 Mar 24
KalVista Pharma Q3 EPS $(0.84) Misses $(0.77) Estimate
11 Mar 24
Press releases
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
3 Apr 24
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
18 Mar 24
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
12 Mar 24
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
11 Mar 24